Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05965570 · ClinicalTrials.gov registry record · Phase 1
A Study to Investigate Effect of Clarithromycin, a Strong CYP3A4 Inhibitor, on Brensocatib Pharmacokinetics in Healthy Participants
A Phase 1 study, sponsored by Insmed Incorporated.
- Completed
- Registry status
- Phase 1
- Development phase
- 22
- Enrollment target
NCT05965570 is a Phase 1 study that has completed, run by Insmed Incorporated. The registered enrollment target is 22 participants.
The verdict
NCT05965570, a Phase 1 study, has completed, sponsored by Insmed Incorporated.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 22 participants
- Enrollment target
Study Summary
The primary purpose of this study is to determine the effect of clarithromycin on the single-dose pharmacokinetics (PK) of brensocatib in healthy participants.
Interventions
- DRUG Clarithromycin
- DRUG Brensocatib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 22 participants |
| Start Date | 2023-07-28 |
| Est. Completion | 2023-09-22 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05965570
The ClinicalTrials.gov registry entry for NCT05965570 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 22 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Insmed Incorporated, which has 31 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Clarithromycin is the first listed.
NCT05965570 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05965570 about?
NCT05965570 is a clinical study titled "A Study to Investigate Effect of Clarithromycin, a Strong CYP3A4 Inhibitor, on Brensocatib Pharmacokinetics in Healthy Participants". The primary purpose of this study is to determine the effect of clarithromycin on the single-dose pharmacokinetics (PK) of brensocatib in healthy participants.
What is the current status of trial NCT05965570?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 22 participants. The study started on 2023-07-28. Estimated completion is 2023-09-22.
What interventions are being tested in trial NCT05965570?
The interventions under investigation include: Clarithromycin (DRUG), Brensocatib (DRUG).
Who is sponsoring clinical trial NCT05965570?
This trial is sponsored by Insmed Incorporated, which has 31 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.